Maria-Cristina Loomis

This inventor holds 25 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Antibody Therapeutics. Top assignees: H. Lundbeck A/s, Alderbio Holdings LLC, University of Iowa Research Foundation. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Maria-Cristina Loomis. Retrieved from https://idiyas.com/inventor/maria-cristina-loomis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 6)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 8)

EPO Patents = 3 (Patent Applications = 12)

Average Co-Inventor Count = 13.2

ph-index = 7

Forward Citations = 115(Granted Patents)

Company Filing History:

Alderbio Holdings LLC

patents

3 out of 925

University of Iowa Research Foundation

patents

4. 1 out of 8

Alder Biopharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...

Areas of Expertise:

Anti-PACAP Antibodies

Anti-CGRP Compositions

Nucleic Acids

Humanized Antibodies

Treatment Methods

Migraine Therapy

Photophobia Treatment

Antigen Binding Fragments

Screening Methods

Headache Conditions

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12747291 - NUCLEIC ACIDS ENCODING HUMANIZED ANTI-PACAP ANTIBODIES (2026-09-29),

2. 12545725 - Anti-PACAP antibodies, nucleic acids and methods of making thereof (2026-02-10),

3. 12162936 - Methods of treatment with anti-PACAP antibodies (2024-12-10),

4. 12077581 - Anti-PACAP antibodies and uses thereof (2024-09-03),

5. 11993648 - Screening method for identifying anti-PACAP antibodies or antibody fragments suitable for use in treating or preventing PACAP-associated photophobia or light aversion (2024-05-28),

6. 11938185 - Treatment of headache, migraine and/or photophobia conditions using humanized anti-PACAP antibodies (2024-03-26),

7. 11352409 - Anti-PACAP antibodies and uses thereof (2022-06-07),

8. 11254741 - Anti-PACAP antibodies (2022-02-22),

9. 11111289 - Anti-CGRP compositions and use thereof (2021-09-07),

10. 10981985 - Anti-PACAP antibodies (2021-04-20),

11. 10981984 - Methods of determining whether anti-PACAP antibodies inhibit PACAP-associated photophobia or light aversion (2021-04-20),

12. 10975135 - Humanized anti-PACAP antibodies (2021-04-13),

13. 10968268 - Humanized anti-PACAP antibodies (2021-04-06),

14. 10954285 - Humanized anti-PACAP antibodies (2021-03-23),

15. 10913783 - Humanized anti-PACAP antibodies and uses thereof (2021-02-09),

Title: **Maria-Cristina Loomis: Innovator in Anti-PACAP Antibodies**

Introduction

Maria-Cristina Loomis, located in Bothell, WA, is an accomplished inventor with a remarkable portfolio of 23 patents. Her contributions to the field of biotechnology, particularly in the development of methods related to anti-PACAP antibodies, have significantly advanced medical treatment options.

Latest Patents

Among her latest innovations, Maria-Cristina has developed methods of treatment utilizing antagonistic antibodies and antigen binding fragments that specifically target PACAP (Pituitary Adenylate Cyclase Activating Polypeptide). These antibodies are designed to inhibit, block, or neutralize biological effects associated with PACAP, such as vasodilation. The inventions elaborate on the use of these antibodies for diagnosing, assessing, and treating diseases linked to PACAP, notably conditions like headaches and migraines. The focus on specific epitopes on human PACAP further emphasizes the precision of these innovative treatments.

Career Highlights

Throughout her career, Maria-Cristina has demonstrated a strong commitment to advancing therapeutic solutions. She has worked with notable companies such as H. Lundbeck A/S and Alderbio Holdings LLC, where her research has had a substantial impact on the development of therapeutic antibodies. This experience showcases her dedication and expertise in the biotechnology industry.

Collaborations

Maria-Cristina has collaborated with esteemed colleagues, including Benjamin H. Dutzar and John A. Latham. These partnerships highlight the collaborative nature of research and innovation in the field, enabling the sharing of ideas and expertise that lead to groundbreaking advancements.

Conclusion

Maria-Cristina Loomis stands as a prominent figure in the landscape of biotechnology, with her inventive efforts paving the way for new treatments and improved patient outcomes. Her work on anti-PACAP antibodies not only reflects her dedication as an inventor but also marks significant milestones in the fight against conditions linked to PACAP. Her continued contributions will likely shape future innovations in the medical field.

Profile summary based on public USPTO records.